SCHEMBL22540919

SCHEMBL22540919

NNC(=O)c1cc(N)cc(C(F)(F)F)n1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 4/20 0.59
ALDH1A1 P00352 5/20 0.40
NPSR1 Q6W5P4 1/20 0.39
MAPT P10636 3/20 0.39
HTT P42858 1/20 0.39
GAA P10253 3/20 0.38
HSP90AA1 P07900 1/20 0.36
HSP90AB1 P08238 1/20 0.36
TP53 P04637 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
KDM4E B2RXH2 1/20 0.35
CFTR P13569 1/20 0.35
CYP1A2 P05177 2/20 0.34
CD38 P28907 2/20 0.34
CYP2C19 P33261 1/20 0.34
CDK8 P49336 1/20 0.34
CDK19 Q9BWU1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27077029 0.81 ALOX15 (0.41) P2RX7ALDH1A1MAPTGAAHSP90AA1
SCHEMBL30697188 0.81 ALOX15 (0.41) P2RX7ALDH1A1MAPTGAAHSP90AA1
SCHEMBL22695513 0.81 LMNA (0.42) P2RX7ALDH1A1NPSR1HSP90AA1HSP90AB1
SCHEMBL29882592 0.79 HSP90AA1 (0.42) P2RX7ALDH1A1NPSR1HSP90AA1HSP90AB1
SCHEMBL18839634 0.79 HSP90AA1 (0.42) P2RX7ALDH1A1NPSR1HSP90AA1HSP90AB1
SCHEMBL2342015 0.79 NQO2 (0.46) P2RX7ALDH1A1MAPTHSP90AA1HSP90AB1
SCHEMBL22540911 0.78 P2RX7 (0.54) P2RX7ALDH1A1NPSR1MAPTHTT
SCHEMBL23580468 0.75 KDM4E (0.47) ALDH1A1NPSR1MAPTGAATP53
SCHEMBL29882458 0.75 KDM4E (0.47) ALDH1A1NPSR1MAPTGAATP53
SCHEMBL2552127 0.75 P2RX7 (1.00) P2RX7ALDH1A1MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020210508-A1 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE OF A CBL-B INHIBITOR IN COMBINATION WITH A CANCER VACCINE AND/OR ONCOLYTIC VIRUS NURIX THERAPEUTICS, INC. (US) 2020-10-15 WO disclosed